Drug Trial Radar · NCT05885503
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Sep 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
316
Planned (sponsor's estimate)
Start
Jun 8, 2023
Primary completion
Jun 2026
Study completion Jun 2026
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy and safety of RC28-E compared with Aflibercept in subjects with diabetic macular edema.
Conditions
- Diabetic Macular Edema
Interventions
RC-28EBiological
Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
AfliberceptBiological
Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in BCVA at Week 52Time frame: Baseline, week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.